DEP方案治疗34例晚期胃癌的临床观察

Clinical observation of DEP regimen as therapy for 34 patients with advanced gastric cancer

为了观察多西紫杉醇联合表柔比星加顺铂（DDP）方案（DEP）治疗晚期胃癌的临床疗效和毒副反应,对入组的34例晚期胃癌患者给予表柔比星50 mg/m2,d1,多西紫杉醇75 mg/m2,d2,DDP 25 mg/m2,d3~d53周方案全身化疗。34例患者中完全缓解（CR）5例（14.71%）,部分缓解（PR）15例（44.12%）,稳定（SD）6例（17.65%）,进展（PD）8例（23.53%）,总有效率（CR＋PR）为58.82%（20/34）,疾病控制率（CR＋PR＋SD）为76.47%（26/34）。毒副反应主要为骨髓抑制,发生率为94.12%（32/34）,其中Ⅲ、Ⅳ级占29.41%,无治疗相关性死亡。初步研究结果提示,PEP方案治疗晚期胃癌疗效肯定,虽然骨髓抑制等不良反应偏高,但有一定的治疗优势,值得进一步在临床中推广应用。

The objective of this study was to evaluate the toxicity and efficacy of combination chemotherapy with docetaxel and epirubicin plus cisplatin regimen（DEP） in patient with advanced gastic cancer.Totally 34 patients were consecutively enrolled in this study.Epirubicin 50 mg/m2,iv,d1 and Docetaxel 75 mg/m2,iv,d2,plus cisplatin 25 mg/m2,iv,d3-d5 were administered every three weeks.There are 5 cases CR（14.71%） and 15 cases PR（44.12%）,6 cases SD（17.65%） and 8 cases PD（23.53%）.Overall response rate（CR＋PR） was 58.82%（20/34）.Disease control rate was 76.47%（26/34）.And 94.12%（32/34） patients experienced bone marrow suppression,of them 29.41% were grade Ⅲ-Ⅳ,which was the most common and serious toxicity.There were no direct treatment-related deaths.In conclusion,docetaxel and epirubicin plus cisplatin regimen（DEP） is active in patient with advanced gastric cancer.Despite its severe hematotoxicity,this regimen has some superiority.It consides that this regimen is feasible and might warrant further investigation in patient with advanced gastic cancer.